tazobactam has been researched along with Liver Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldassarre, M; Barsic, B; Bartoletti, M; Bernardi, M; Bruns, T; Burra, P; Calbo, E; Caraceni, P; Cobos-Trigueros, N; D'Offizi, G; Domenicali, M; Galan-Ladero, MA; Giannella, M; Lewis, RE; Maraolo, AE; Merli, M; Muñoz, P; Paul, M; Petrosillo, N; Retamar, P; Rodriguez-Baño, J; Schramm, C; Seminari, E; Tedeschi, S; Torrani Cerenzia, M; Tumbarello, M; Verucchi, G; Viale, P; Zak-Doron, Y | 1 |
| Chao, CM; Chiu, YH; Hou, CC; Lai, CC; Liu, WL | 1 |
2 other study(ies) available for tazobactam and Liver Cirrhosis
| Article | Year |
|---|---|
Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Female; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Piperacillin; Prospective Studies; Retrospective Studies; Tazobactam; Treatment Outcome | 2019 |
Biliary tract infection caused by Vibrio fluvialis in an immunocompromised patient.
Topics: Abdominal Pain; Aged, 80 and over; Anti-Bacterial Agents; Bile Ducts, Intrahepatic; Choledocholithiasis; Diabetes Mellitus; Diagnosis, Differential; Female; Gallstones; Humans; Immunocompromised Host; Kidney Failure, Chronic; Liver Cirrhosis; Penicillanic Acid; Piperacillin; Risk Factors; Taiwan; Tazobactam; Treatment Outcome; Vibrio; Vibrio Infections; Vomiting | 2011 |